The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-101 NDA for the treatment of Menkes disease.

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

The landscape of pandemic response has been transformed, with new standards being set for clinical excellence. A new report looks at emerging therapies, trial insights, and the innovations shaping the ...

Orbis Medicines has raised €90m ($94m) in Series A funding to advance the development of its next-generation orally dosable macrocycle drugs.

The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.

VYD-2311 is under clinical development by Invivyd and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.

The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

MET-3 is under clinical development by Nubiyota and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II drugs for Hypertriglyceridemia have a 52% phase transition success ...